Artiva (ARTV) Form 4: Horan RSU Withholding of 4,918 Shares Reported

Rhea-AI Filing Summary

Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding. On 05/15/2025 he had 1,341 shares withheld at an effective price of $2.13, reducing his direct ownership to 83,659 shares. On 08/15/2025 he had 3,577 shares withheld at $2.75, reducing his direct ownership to 80,082 shares. The filing identifies Horan as Chief Tech Operations Officer and was signed by an attorney-in-fact on 08/18/2025. The form states these share reductions "represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards," indicating these were not open-market sales but withholding transactions connected to equity compensation.

Positive

• Disclosure of tax-withholding on RSU vesting demonstrates compliance with Section 16 reporting requirements
• Transactions are administrative (withholding) rather than open-market sales, reducing likelihood of signaling liquidity-driven selling

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding on RSU vesting, shows governance-compliant disclosure but no change to control.

The Form 4 discloses withholding of vested restricted stock units to satisfy income taxes, a standard practice that reduces reported beneficial ownership without indicating a voluntary divestiture. This preserves executive compensation mechanics while maintaining transparency. The reductions do not suggest a change in voting control or a disposition for liquidity. Documentation signed by an attorney-in-fact is common for administrative filings.

Securities Analyst

TL;DR: Non-market withholding lowers share count modestly; no evidence of opportunistic selling or material ownership shift.

The transactions are labeled as tax-withholding from RSU vesting, with 1,341 shares withheld at $2.13 and 3,577 shares withheld at $2.75, bringing direct holdings to 80,082 shares. For a public company, these amounts are minor relative to typical outstanding share counts and do not meet materiality thresholds for investor-impactful events. The reporting is consistent with Section 16 requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horan Christopher

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Tech Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2025		F		1,341(1)	D	$2.13	83,659	D
Common Stock	08/15/2025		F		3,577(1)	D	$2.75	80,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Neha Krishnamohan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Christopher Horan report on the Form 4 for ARTV?

He reported two withholding transactions: 1,341 shares withheld at $2.13 on 05/15/2025 and 3,577 shares withheld at $2.75 on 08/15/2025 to satisfy income tax on vested RSUs.

Do the reported transactions represent open-market sales of ARTV stock?

No. The form states the shares were withheld by the issuer to satisfy income tax obligations associated with RSU vesting, not sales on the open market.

How many ARTV shares does Horan beneficially own after the transactions?

After the 05/15/2025 withholding his ownership was 83,659 shares; after the 08/15/2025 withholding his ownership was 80,082 shares.

What is Christopher Horan's role at Artiva Biotherapeutics as listed on the Form 4?

He is listed as Chief Tech Operations Officer and an officer of the issuer.

Who signed the Form 4 submission for these transactions?

The filing was signed by Neha Krishnamohan, Attorney-in-Fact, on 08/18/2025.